Barrington Research Raises Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX) – Equities researchers at Barrington Research boosted their FY2025 EPS estimates for shares of Surmodics in a research report issued to clients and investors on Thursday, November 7th. Barrington Research analyst M. Petusky now anticipates that the company will earn $0.21 per share for the year, up from their prior estimate of $0.19. The consensus estimate for Surmodics’ current full-year earnings is $0.16 per share. Barrington Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.17 EPS.

A number of other equities analysts also recently issued reports on the company. StockNews.com assumed coverage on Surmodics in a research note on Thursday. They set a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $50.00.

Surmodics Price Performance

Shares of NASDAQ:SRDX opened at $38.46 on Friday. Surmodics has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a 50-day moving average price of $38.57 and a 200 day moving average price of $38.69. The company has a market cap of $548.82 million, a P/E ratio of -47.48 and a beta of 1.20. The company has a quick ratio of 3.22, a current ratio of 3.98 and a debt-to-equity ratio of 0.25.

Institutional Investors Weigh In On Surmodics

Institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC raised its holdings in Surmodics by 11.3% during the first quarter. Acadian Asset Management LLC now owns 408,779 shares of the company’s stock worth $11,988,000 after purchasing an additional 41,617 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Surmodics by 5.0% during the 2nd quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock worth $25,499,000 after buying an additional 28,990 shares during the last quarter. Gardner Lewis Asset Management L P purchased a new stake in shares of Surmodics in the 2nd quarter worth about $8,531,000. Sagefield Capital LP acquired a new stake in Surmodics in the 2nd quarter valued at about $2,350,000. Finally, Trium Capital LLP purchased a new position in Surmodics during the 2nd quarter valued at about $1,406,000. Hedge funds and other institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).